UNSPSC 51386400: Nonsteroidal anti inflammatory phenylhydrazines

Nonsteroidal anti inflammatory drugs made from diazo derivatives of aniline (benzene and hydrazine, or hydrazinobenzene).

UNSPSC 51386400 Nonsteroidal anti inflammatory phenylhydrazines is a Class code whose title does not match the work state and local governments are actually procuring under it. Recent solicitations tagged to this code involve naloxone (an opioid antagonist), generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription programs — none of which are nonsteroidal anti-inflammatory phenylhydrazines. The code shows a mismatch between its nominal scope and the pharmaceutical and health-services procurement activity it captures in practice. State and local issuing bodies using this code include county health departments, state HHS agencies, and multistate cooperative purchasing alliances; Seminole County, Florida and the Texas Health and Human Services Commission and Minnesota Department of Administration appear in recent postings. The work actually being solicited spans emergency medical supplies (naloxone and drug deactivation systems), generic and OTC pharmaceuticals for government health programs, and pharmacy benefit administration services.

Geographic activity concentrates in Florida, Texas, and Minnesota based on recent opportunities. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, including shipping costs. The Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Department of Administration, administering the multistate cooperative purchasing alliance MMCAP, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026. These solicitations suggest ongoing state and local demand for pharmaceutical supply management and emergency health services, though the code's mislabeling creates potential discoverability risk for vendors in related product categories.